雷公藤多苷片联合复方α酮酸片治疗糖尿病肾病的临床观察.docxVIP

雷公藤多昔片联合复方a -酮酸片治疗 糖尿病肾病的临床观察 刘凌汐于洋 武汉市普仁医院 摘要： 口的:观察雷公藤多昔片联合复方Q-酮酸片治疗糖尿病肾病(DN)的疗效和安 全性。方法：186例糖尿病肾病患者随机分为对照组(93例)和研究组(93例)。 在常规治疗的基础上，对照组患者给予雷公藤多昔片20 mg, 口服，毎H3次； 研究组患者在对照组治疗的基础上给予复方a-酮酸片3. 78 g, 口服，每日3 次。两组均连续治疗3个月。观察两组患者的临床疗效，治疗前肾功能［肌酹 (Scr)、尿素氮(BUN)、胱抑素C (Cys C)、肾小球滤过率(GFR)、24 h尿 蛋口］、肾间质纤维化指标［血清同型半胱氨酸(Hey)、血管内皮生长因子 (VEGF)、肝细胞生长因子(HGF)、转化生长因子A (TGF-B J ］、氧化应激 指标［总抗氧化能力(T-A0C)、超氧化物歧化酶(S0D)、晚期蛋白氧化产物 (AOPP)、丙二醛(MDA)］水平及不良反应发生情况。结果：两组患者治疗过程 屮未出现患者脱落，均完成治疗。研究组患者总有效率(91.39%)显著高于对照 组(80. 65%),差异有统计学意义(P0. 05) o治疗后，两组患者Ser、BUN. Cys C、24 h尿蛋白、Hey、VEGF、TGF-A、AOPI\ MDA水平均显著低于同组治 疗前，且研究组显著低于对照组;两组患者GFR、HGF、T-AOC. SOD水平均显著高 于同组治疗前，口研究组显著高于对照组，差异均有统计学意义(P0. 05)。两 组患者不良反应发生率比较，差异无统计学意义(P0. 05)。结论：雷公藤多昔 片联合复方a-酮酸片治疗DN的疗效显著，且未增加不良反应的发生。 关键词： 糖尿病肾病;雷公藤多昔片;复方-酮酸片;疗效;安全性; 作者简介：刘凌汐，副主任医师。研究方向：肾脏病。E-mail:807061039@qq. com 收稿日期：2016-12-13 Clinical Observation of Tripterygium Tablets Combined with Compound a -Keto Acid Tablets in the Treatment of Diabetic Nephropathy LIU Lingxi YU Yang Wuhan Puren Hospital; Abstract： OBJECTIVE:To observe therapeutic efficacy and safcty of Tripterygium tablets combined with Compound a -keto acid tablcts in the treatment of diabetic nephropathy (DN) patients. METHODS:A total of 186 DN patients were randomly divided into control group (93 cases) and study group group (93 cases) ? Based on routine treatment, control group was given Tripterygium tablet 20 mg orally, 3 times a day;study group was additionally given Compound a -keto acid tablet 3. 78 g orally, 3 times a day, on the basis of control group. Both groups were treated for consecutive 3 months. Clinical efficacies of 2 groups were observed, and the levels of renal function indexes (Scr, BUN, CysC, GFR, 24 h urine protein) , renal interstitial fibrosis indexes (Iley, VEGF, IIGF, TGF-BJ and oxidative stress indexes (T-AOC, SOD, AOPP, MDA) , the occurrence of ADR were also observed before and after treatment. RESULTS:No patient withdrew from the experiment in 2 groups, and all completed the treatment